Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu 210042, China.
Chin Med J (Engl). 2012 Jun;125(11):1920-4.
Treponema pallidum (T. pallidum) subsp. pallidum is the causative agent of syphilis. Analysis of recombinant antigens of T. pallidum led to the identification of potential candidate antigens for vaccine development and syphilis serodiagnosis. Tp0965 was predicted to be a membrane fusion protein and was found to be reactive with infected human sera in previous studies, but the results were controversial. In this research, the antigenicity and immunoreactivity of recombinant protein Tp0965 were assessed.
T. pallidum subsp. pallidum (Nichols strain) was propagated and isolated and the genomic DNA was extracted. The Tp0965 gene was amplified by polymerase chain reaction (PCR). Then the recombinant protein Tp0965 was expressed in Escherichia coli and purified by nickel-nitrilotriacetic acid (Ni-NTA) purification system. The reactivities of protein Tp0965 were examined by immunoblot analysis and indirect enzyme-linked immunosorbent assay. The antisera against protein Tp0965 were obtained by immune rabbits and the immunogenicity of antisera were detected by indirect enzyme-linked immunosorbent assay.
Recombinant protein Tp0965 was expressed successfully in vitro. Immunoblot assay showed that the recombinant protein Tp0965 could be recognized by human syphilitic sera of all stages. Indirect enzyme-linked immunosorbent assay showed there were only 4 of 74 human syphilitic sera that failed to show reactivity to recombinant antigen Tp0965, and lack of reactivity of Tp0965 to all 28 uninfected sera. A low titer of antiserum against Tp0965 in immune rabbits could be detected after the third time of immunization.
The recombinant antigen Tp0965 shows excellent sensitivity for the reactivity with sera from syphilitic individuals at all stages. The results also demonstrate a potential application for the serodiagnosis of syphilis.
苍白密螺旋体(T. pallidum)亚种苍白密螺旋体是梅毒的病原体。苍白密螺旋体重组抗原的分析导致了疫苗开发和梅毒血清学诊断的潜在候选抗原的鉴定。Tp0965 被预测为一种膜融合蛋白,在以前的研究中发现它与感染人类血清反应,但结果存在争议。在这项研究中,评估了重组蛋白 Tp0965 的抗原性和免疫反应性。
苍白密螺旋体亚种苍白密螺旋体(Nichols 株)繁殖和分离,并提取基因组 DNA。通过聚合酶链反应(PCR)扩增 Tp0965 基因。然后,在大肠杆菌中表达重组蛋白 Tp0965,并通过镍-亚氨基二乙酸(Ni-NTA)纯化系统进行纯化。通过免疫印迹分析和间接酶联免疫吸附试验检查蛋白 Tp0965 的反应性。通过免疫兔子获得针对蛋白 Tp0965 的抗血清,并通过间接酶联免疫吸附试验检测抗血清的免疫原性。
重组蛋白 Tp0965 在体外成功表达。免疫印迹分析显示,重组蛋白 Tp0965 可被各期人类梅毒血清识别。间接酶联免疫吸附试验显示,只有 74 份人类梅毒血清中有 4 份未能显示对重组抗原 Tp0965 的反应性,而 Tp0965 对所有 28 份未感染血清均无反应性。免疫兔子的抗血清在第三次免疫后可检测到低滴度的 Tp0965。
重组抗原 Tp0965 对各期梅毒患者血清的反应性具有极好的敏感性。结果还表明,它具有用于梅毒血清学诊断的潜在应用。